MNKD
HealthcareMannKind Corporation · Biotechnology · $1B
What is MannKind Corporation?
MannKind Corporation is a biopharmaceutical company focused on inhaled therapeutic products for endocrine and orphan lung diseases. Headquartered in Westlake Village, California, it targets underserved patient populations with specialized delivery technologies.
MannKind generates revenue primarily through Afrezza, an inhaled insulin designed to improve blood sugar control in adults with diabetes. The company also promotes Thyquidity for hypothyroidism treatment and holds a collaboration agreement with United Therapeutics Corporation. Additionally, MannKind is developing a dry powder formulation of aviptadil (ZYESAMI) in partnership with NRx Pharmaceuticals, targeting inflammatory lung conditions — broadening its pipeline beyond its core diabetes franchise.
MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
- Afrezza — inhaled insulin for adult diabetes management
- Thyquidity — liquid thyroid hormone for hypothyroidism
- Aviptadil (ZYESAMI) dry powder — pipeline treatment for inflammatory lung conditions
- United Therapeutics collaboration — licensed inhaled therapeutics development
Is MNKD a Good Stock to Buy?
UQS Score rates MNKD as Below Average overall, reflecting meaningful structural challenges across several key pillars.
The Growth pillar stands out as the clearest positive signal for MannKind — the company is expanding its commercial footprint and pipeline in ways that differentiate it from peers at a similar stage. This growth trajectory is the primary reason MNKD warrants attention from investors comfortable with higher-risk, earlier-stage biopharmaceuticals.
Quality, Moat, and Risk all register as Weak, pointing to thin competitive insulation, financial fragility, and execution uncertainty. Valuation is rated Elevated, meaning the market may already be pricing in optimistic outcomes.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does MNKD pay dividends?
No — MannKind Corporation does not currently pay a dividend.
MannKind does not currently pay a dividend. For a commercial-stage biopharmaceutical company still investing heavily in product launches and pipeline development, retaining capital is the expected approach. Investors in MNKD are generally seeking growth from product adoption rather than income from distributions.
When does MNKD report earnings?
MannKind Corporation reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
Revenue trends have been shaped by Afrezza prescription growth and the ramp of newer products like Thyquidity. Pipeline milestones and collaboration payments from United Therapeutics can also influence quarterly results meaningfully.
For the most recent quarter's results and guidance, visit MannKind Corporation's investor relations page directly.
MNKD Price History
-38.9% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in MannKind Corporation?
Based on MannKind Corporation's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
MNKD Long-term Outlook
MannKind's fundamental outlook is shaped by the tension between a Good Growth profile and Weak Quality and Risk ratings. The company has real commercial momentum behind Afrezza and is diversifying through Thyquidity and its pipeline — but the path to durable profitability remains uncertain. The Elevated Valuation rating suggests the current share price may leave limited room for error if growth targets slip.
Growth drivers
- Continued Afrezza prescription volume growth in the adult diabetes market
- Thyquidity commercial expansion among endocrinologists
- Pipeline milestones from the United Therapeutics collaboration and aviptadil development
Key risks
- Weak Quality and Risk pillar ratings signal financial and operational fragility
- Elevated Valuation leaves little margin of safety if execution disappoints
- Competitive pressure from established insulin and thyroid therapy providers
MNKD vs Peers
MannKind operates in a niche corner of specialty biopharmaceuticals, where it competes with other smaller companies focused on inhaled or specialty-delivered therapeutics.
LB Pharmaceuticals focuses on central nervous system therapeutics, occupying a different disease area than MannKind's endocrine and lung disease focus.
Theravance Biopharma develops inhaled medicines for respiratory diseases, making it a closer delivery-technology peer to MannKind's inhaled insulin platform.
Alto Neuroscience targets precision psychiatry, sharing the small-cap biopharmaceutical risk profile with MannKind but in an entirely different therapeutic category.
Frequently Asked Questions
What does MannKind Corporation do?
MannKind is a biopharmaceutical company that develops and commercializes inhaled therapeutic products. Its lead product, Afrezza, is an inhaled insulin for adults with diabetes. The company also markets Thyquidity for hypothyroidism and is developing pipeline assets in collaboration with United Therapeutics and NRx Pharmaceuticals.
Does MNKD pay dividends?
No, MannKind does not currently pay a dividend. The company is in a growth and commercialization phase, prioritizing capital allocation toward product launches and pipeline development rather than returning cash to shareholders through distributions.
When does MNKD report earnings?
MannKind reports financial results on a quarterly basis, in line with standard US-listed company practice. For the exact timing of upcoming earnings releases, check MannKind's investor relations page for the most current schedule.
Is MNKD a good stock to buy?
UQS Score rates MNKD as Below Average overall. The Growth pillar is the standout positive, but Quality, Moat, and Risk are all rated Weak, and Valuation is Elevated. Whether it suits your portfolio depends on your risk tolerance and investment horizon. View the full pillar breakdown on UQS Pro.
Is MNKD overvalued?
The UQS Valuation pillar for MNKD is rated Elevated, suggesting the current market price may reflect optimistic assumptions about future growth. Investors should weigh this against the Weak Quality and Risk ratings before drawing conclusions about fair value.
How does MNKD compare to its competitors?
Among small-cap specialty biopharmaceutical peers, MannKind's inhaled delivery focus sets it apart from companies like Theravance Biopharma, which also targets inhaled medicines but in respiratory disease. MNKD's UQS profile can be compared side-by-side with peers using the full competitor view available to Pro members.
What is MNKD's market cap bracket?
MannKind Corporation is classified as a small-cap company. This places it in a segment of the market that typically carries higher volatility and liquidity risk compared to mid-cap or large-cap biopharmaceutical peers.
Who founded MannKind Corporation?
MannKind Corporation was founded by Alfred E. Mann, a prominent medical device and biopharmaceutical entrepreneur. The company was incorporated in 1991 and has been focused on inhaled drug delivery technology throughout its history.
Is MNKD a long-term quality investment?
From a long-term quality perspective, MNKD's UQS profile presents a mixed picture. The Good Growth rating indicates commercial momentum, but Weak scores on Quality, Moat, and Risk suggest the business lacks the durable competitive advantages typically associated with long-term compounders. Pro members can access the complete analysis.
What is the main competitive advantage of MannKind Corporation?
MannKind's primary differentiator is its proprietary Technosphere inhaled drug delivery platform, which enables rapid-acting insulin delivery through inhalation rather than injection. This technology underpins Afrezza and forms the basis for its pipeline collaborations, though the UQS Moat pillar currently rates this advantage as Weak.
What sector does MNKD belong to?
MannKind Corporation operates in the Healthcare sector, specifically within the biopharmaceutical industry. It focuses on specialty therapeutic areas including endocrine diseases such as diabetes and hypothyroidism, as well as orphan lung diseases through its pipeline programs.
Is MNKD a growth stock or value stock?
Based on its UQS profile, MNKD leans toward the growth category — the Growth pillar is rated Good, reflecting commercial expansion. However, the Elevated Valuation rating means investors are not getting this growth at a discount, which complicates a straightforward growth-at-reasonable-price thesis.
Unlock Full MNKD Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores for MNKD
- ✓Access full financial metrics and trend data
- ✓Compare MNKD against sector peers side-by-side
- ✓See the complete Quality and Risk factor breakdown
- ✓Track UQS Score changes over time
- ✓Explore curated screens for small-cap healthcare stocks
Pro Analysis
MNKD — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 10, 2026 | 41.4 | 12.4 | 26.0 | 78.9 | 39.9 | 67.2 | +1.2 |
| May 8, 2026 | 40.2 | 12.4 | 26.0 | 78.9 | 39.9 | 59.2 | 0.0 |
| May 7, 2026 | 40.2 | 29.6 | 26.0 | 78.9 | 34.9 | 34.9 | -0.5 |
| May 3, 2026 | 40.7 | 29.6 | 26.0 | 78.9 | 34.9 | 38.4 | -0.1 |
| May 1, 2026 | 40.8 | 29.6 | 26.0 | 78.9 | 34.9 | 39.0 | -0.1 |
| Apr 26, 2026 | 40.9 | 29.6 | 26.0 | 78.9 | 34.9 | 40.1 | +0.5 |
| Apr 19, 2026 | 40.4 | 29.6 | 26.0 | 78.9 | 34.9 | 36.4 | -0.7 |
| Apr 18, 2026 | 41.1 | 30.0 | 26.0 | 78.9 | 34.9 | 40.7 | -0.7 |
| Apr 16, 2026 | 41.8 | 30.0 | 26.0 | 78.9 | 34.9 | 45.5 | +0.1 |
| Apr 14, 2026 | 41.7 | 30.0 | 26.0 | 78.9 | 34.9 | 44.8 | -0.1 |
MNKD — Pillar Breakdown
Quality
— 37.5/100 (25%)MannKind Corporation has average quality metrics, with room for improvement in margins or capital efficiency.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 78.9/100 (20%)MannKind Corporation is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 36.4/100 (15%)MannKind Corporation has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 37.4/100 (15%)MannKind Corporation has a mixed valuation — some metrics suggest fair value while others appear stretched.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 26/100 (25%)MannKind Corporation operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for MNKD.
Score Composition
Financial Data
More Stock Analysis
How is the MNKD UQS Score Calculated?
The UQS (Unified Quality Score) for MannKind Corporation is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses MannKind Corporation's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether MannKind Corporation is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.